Market News AIOpen the app

The European Commission has approved Ionis' TRYNGOLZA™ to treat severe high triglycerides.

TrialRead the original at fidelity.com
Good for IONS

Ionis won EU approval for TRYNGOLZA, backed by studies showing lower triglyceride levels. Sobi holds exclusive sales rights outside the U.S., except in China and Canada, but the approval still opens a new market.

IONS · Ionis Pharmaceuticals

AI read · Good for IONS

The AI's read

The study results support TRYNGOLZA’s ability to lower triglycerides, and EU approval opens a new approved market. Sobi holds exclusive sales rights outside the U.S., except in China and Canada, so Ionis relies on a partner there.

Get alerts for IONS

Follow Ionis Pharmaceuticals (IONS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IONS
Free on the App Store and Google Play, or on the web.